A phase I/II clinical trial of carbon ion radiotherapy with concurrent S-1 for operable pancreatic cancer(HIMAT1325)

A phase I/II clinical trial of carbon ion radiotherapy with concurrent S-1 for operable pancreatic cancer(HIMAT1325) - Preoperative carbon-ion radiotherapy with S-1 chemotherapy for operable pancreatic cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016436

Enrollment

Registered

2015-02-05

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

operable pancreatic cancer

Interventions

Carbon-ion radiotherapy Chemotherapy (S-1) Surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Stage I-IIB (UICC) 2)Pathologically diagnosed pancreatic invasive ductal carcinoma 3)No past history of treatment for pancreatic cancer 4)Planning target volume is less than 15cm 5)include evaluable lesion 6)Age under 75 years old 7)P 0-1 8)Sufficient major organ function 9)Informed consent by patient

Exclusion criteria

Exclusion criteria: 1)Metallic stent at the bile duct 2)Invasion to mucosal membrane of stomach or intestine 3)Use of flu cytosine, phenytoin, or warfarin potassium 4)Past history of irradiation to the target region 5)Active double cancers 6)Uncontrolled severe infection 7)Uncontrolled severe complication 8)Other medical or psychological unsuitable reasons

Design outcomes

Primary

Measure	Time frame
Phase 1: normal tissue effect during observation period Phase 2: local control rate	—

Countries

Japan

Contacts

Public ContactKotaro Terashima

SAGA HIMAT Foundation Ion Beam Therapy Center

terashima-kotaro@saga-himat.jp0942-81-1897

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026